# A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

> **NCT05030324** · PHASE2 · COMPLETED · sponsor: **Valenta Pharm JSC** · enrollment: 255 (actual)

## Conditions studied

- Influenza
- Viral Respiratory Infection
- Acute Viral Upper Respiratory Infections

## Interventions

- **DRUG:** XC221 100 mg
- **DRUG:** XC221 200 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05030324
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-01
- **Primary completion:** 2022-05-04
- **Final completion:** 2022-05-04
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05030324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05030324, "A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05030324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*